However, the predictive value of GDF-15 levels for the risk of cardiotoxicity induced by neoadjuvant dual anti-HER2 therapy has not been reported in HER2-positive breast cancer patients, which is clinically important. This evidence concerns the gene ERBB2 and breast cancer.